Mitsubishi UFJ Asset Management
CRVS icon

Mitsubishi UFJ Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.8K Buy
+3,200
New +$44.4K ﹤0.01% 1133

Other funds holding CRVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mitsubishi UFJ Asset Management's CRVS Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 3,200 shares worth $47.8K. The stake represents ﹤0.01% of the portfolio and ranks #1133 among its holdings.

59 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Mitsubishi UFJ Asset Management held 3,200 shares of Corvus Pharmaceuticals worth $47.8K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Mitsubishi UFJ Asset Management position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #1133 holding.
  • 59 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.